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Abstract A connecting decapeptide corresponding to rat pre-
pro-TRH-(160-169) (Ps4) displays several biological activities 
that are related or unrelated to TRH. We have previously 
characterized pituitary binding sites for this connecting peptide 
and elucidated structural determinants for high peptide binding 
affinity. In the current study, a series of cell lines was screened 
for the presence of specific binding sites with a highly potent 
derivative of Ps4, the monoiodinated radioligand |125I-Tyr ]Ps4. 
Neuroblastoma X glioma hybrid NG108-15, glioma C6 and 
neuroblastoma BN1010 cell lines were found to have high-
affinity |,25I-Tyr°lPs4 binding sites containing 600, 9700 and 
130000 sites/cell, respectively. The specific binding of |12SI-
Tyr°lPs4 was rapid, time-dependent, reversible and proportional 
to the amount of C6 and BN1010 membrane preparation. 
Furthermore, Scatchard or Hill analysis revealed that |12SI-
Tyr°lPs4 was bound by a single population of non-interacting 
sites with dissociation constants in the subnanomolar range. 
Competition studies made with Ps4 analogues indicated that 
[125I-Tyr°]Ps4 binding sites on C6 and BN1010 cells were similar 
to those previously described on rat pituitary membranes. It is 
concluded that C6 and BN1010 cells are suited for studies on the 
intracellular events following binding of the Ps4 and for the 
molecular characterization of the Ps4 binding sites. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Rat prepro-TRH is a 255-amino-acid polypeptide contain-
ing five copies of the TRH progenitor sequence, Gln-His-
Pro-Gly, each flanked by paired basic amino acids (Lys-
Arg or Arg-Arg) and linked together by connecting peptide 
sequences sharing no identity with TRH [1]. Like other plu-
rifunctional prohormone proteins, pro-TRH undergoes differ-
ential proteolytic processing in various tissues to generate, in 
addition to authentic TRH, several other novel peptides cor-
responding to C-terminally extended forms of TRH and con-
necting fragments [2-A]. 
Although the physiological significance of TRH in the reg-
ulation of the pituitary-thyroid axis has been well established 
(for a recent review, see reference [5]), the role of pro-TRH 
connecting peptides is still not clear. In that context, we have 
reported a specific potentiation of TRH-induced thyrotropin 
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(TSH) release by pituitary fragments in vitro by the connect-
ing peptide prepro-TRH-(160-169) (Ps4) [6]. Interestingly, it 
was demonstrated that Ps4, like TRH, induces a dose-depend-
ent increase of ß-TSH mRNA content in intact animals, pri-
mary pituitary cell cultures and in a heterologous TSH ex-
pression assay [7,8]. Recently, another group has revealed 
the biological importance of Ps4 in the dorsal motor nucleus 
of the vagus, a region where TRH plays a pivotal role to 
activate directly neurons leading to the stimulation of vagai 
outflow to the stomach and gastric function. Thus, Ps4 was 
shown to potentiate the action of TRH in the rat CNS to 
stimulate gastric acid secretion [9]. 
Using [125I-Tyr°]Ps4 as a metabolically stable radioligand 
derivative, specific binding sites have been detected in the 
distal lobe of the pituitary by autoradiography [6]. The exist-
ence of a single homogeneous population of high-affinity 
(Kti = 0.22 nM) binding sites for [
125I-Tyr°]Ps4 was demon-
strated in the homogenates of rat pituitary membrane. We 
have shown that the Ps4 binding sites were distinct from the 
TRH receptors and that there was no interaction between Ps4 
and TRH for receptor binding [10]. We have also shown that 
Ps4 and its binding sites were largely distributed in the rat 
brain and peripheral tissues [11]. 
Significant levels of [125I-Tyr°]Ps4 binding sites were de-
tected in the neuronal tissues containing an important amount 
of Ps4, such as the hypothalamus, spinal cord, and olfactory 
lobes. These findings reinforce the suggestion that Ps4 is not 
only a hypophysiotropic hormone but may also act as a neu-
romodulator or neurotransmitter in the CNS. Whereas bind-
ing characteristics of the Ps4 pituitary binding sites and mo-
lecular determinants for binding affinity have been clearly 
defined, little is known about the structure of the Ps4 binding 
sites and the molecular mechanism(s) by which Ps4 elicits its 
physiological effects. Since this gap in knowledge is due in 
large part to the lack of Ps4-responsive cellular models, we 
have screened cell lines of various origin for Ps4 binding sites 
that could be used as a starting material to clone the Ps4 
receptor. 
2. Materials and methods 
2.1. Solid-phase synthesis of prepro-TRH-( 160-169) and analogs 
Prepro-TRH-(160-169) (Ps4), [Tyr°]prepro-TRH-(160-169) ([Tyr°] 
Ps4), prepro-TRH-(158-169) ([Arg-1,Arg°]Ps4), and prepro-TRH-
(159-169) ([Arg°]Ps4) were prepared by stepwise solid phase synthesis 
using Fmoc polyamide active ester chemistry on a Milligen 9050 Pep-
synthesizer as described previously [10]. 
2.2. Cell culture 
The BN1010 cells which are capable of synthesizing TRH were 
derived from an ethylnitrosourea-induced rat CNS tumor [12] and 
C6 cells from a rat glioma [13], Both BN1010 and C6 cell lines 
were cultured on 10-cm-diameter petri dishes in RPMI-1640 medium 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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Fig. 1. Specific binding of [25I-Tyr°]Ps4 to rat C6 membrane homogenates as a function of increasing protein concentrations. [125I-Tyr°]Ps4 (0.2 
nM) were incubated for 120 min with various concentrations of C6 membrane tissues (9.4 ug/ml to 0.6 mg/ml of membrane proteins) and spe-
cific binding was measured as the difference between femtomole bound in the absence and presence of 1 u.M unlabeled [Tyr°]Ps4. Results are 
expressed as femtomole of specific [125I-Tyr°]Ps4 bound and represent the mean of duplicated determinations. 
supplemented with 10 mM HEPES, 10% heat-inactivated fetal calf 
serum, 2 mM L-glutamine, 100 U/ml penicillin and 10 ug/ml strepto-
mycin, in a humidified atmosphere (5% C02/95% air) at 37°C. 
2.3. Receptor binding assays 
After reaching confluency, cells were detached by incubation in 
(Ca2+, Mg2+)-free phosphate-buffered saline (PBS) containing 1 mM 
EDTA for 5 min at 37°C. Cells were then centrifuged and homogen-
ized in 50 mM Tris-HCl, pH 7.4, by four cycles of Polytron and 
centrifugation (20 min, lOOOOXg) at 4°C. The resulting pellet was 
resuspended in the same buffer containing 20% glycerol and stored 
at -80°C. The final protein concentration of the C6 and BN1010 
extract was 2.15 mg/ml and 1.36 mg/ml, respectively, as determined 
by the method of Lowry [14] using bovine serum albumin (BSA) as 
standard. Binding assays were performed as described [10] in 50 mM 
Tris-HCl, pH 7.4, plus 0.1% BSA and 0.01% bacitracin using mono-
iodinated [Tyr°]Ps4 as primary ligand. [Tyr°]Ps4 was iodinated by 
using chloramine-T. Purification of monoiodinated [125I-Tyr°]Ps4 
was performed by reverse-phase HPLC on a Lichrosorb RP-18 col-
umn (5 mm; 25 x 0.4 cm). The specific activity of the peptide was 2000 
Ci/mmol. Briefly, each assay contained, in a final volume of 300 uj, 
the membrane preparation (90 u,g of C6 membrane proteins and 1.13 
|xg of BN1010 membrane proteins) and the iodinated ligand at the 
desired concentration with or without unlabeled ligand. Binding ex-
periments were also performed on viable cells using the same proce-
dure with PBS containing 1 mM HEPES, 5 mg/ml BSA, and 1 mg/ml 
glucose as binding and washing buffers. Specific binding was consid-
ered as the difference in radioactivity trapped on the filters either in 
the absence or presence of 1 uM of the unlabeled primary ligand. All 
determinations were performed in duplicate. The 50% inhibitory con-
centration values (IC5o) were obtained from non-linear least-squares 
regression to a two-parameters logistic equation of the percent specific 
binding versus log(dose) curves. The inhibitory constant (Aj, nM) of 
the various unlabeled ligands was calculated from the relation 
^i=IC50/(l+[L]/A'd) [15] where L is the labeled ligand and Kd its 
equilibrium dissociation constant determined by saturation binding 
analysis. 
Fig. 2. Kinetics of specific association and dissociation of [125I-Tyr°]Ps4. A: C6 membranes (90 ug proteins) were incubated with 0.3 nM [125I-
Tyr°]Ps4 for increasing periods of time to determine the association kinetics at 24°C (•) and 4°C ( A ) . Inset: Dissociation kinetics, at 24°C (•) 
and 4°C ( A ) , were initiated by the addition of 1 uM of unlabeled [Tyr°]Ps4 to the C6 membrane preparations at equilibrium (180 min incuba-
tion). Specific binding was obtained by substracting non-specific binding from total binding. Each point is the average of triplicate determina-
tions obtained from three similar experiments. B: BN1010 membranes (1.13 ug proteins) were incubated with [125I-Tyr°]Ps4 (0.2 nM) for the in-
dicated time intervals and specific binding (•) was measured at 24°C. Similar experiments were performed on BN1010 whole cells (1.35 106 
cells) at 4°C ( A ) . Inset: Dissociation experiments: after 120 min incubation at 4°C ( A ) , 1 u.M of unlabeled [Tyr°]Ps4 was added to the 
BN1010 membranes and radioactivity specifically bound was determined. Results were obtained as described in (A). 
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3. Results and discussion 
3.1. Screening of cell lines for f1251-Tyr°]Ps4 binding sites 
Since Ps4 binding sites are widely distributed in the CNS 
and peripheral tissues [11], we screened a series of neural and 
endocrine cell lines for [125I-Tyr°]Ps4 binding sites. Incuba-
tions were carried out at room temperature for 60 min with 
0.2 nM [125I-Tyr°] Ps4 in the absence or the presence of 1 |J.M 
[Tyr°] Ps4 to determine non-specific binding. Using membrane 
homogenates, we demonstrated that out of the 10 cell lines 
studied, three types of neural cells, i.e. C6 (rat glioma), 
BNIOIO (rat neuroblastoma) and NG 108-15 (neuroblasto-
ma X glioma hybrid), exhibited specific binding sites of [125I-
Tyr°]Ps4 (Table 1). No binding sites were found on the endo-
crine pancreas tumor cell lines RINm5F, INS-1 and ocTC and 
on the pituitary tumor cell lines GH3, SUG, SUF and GC. 
Rat C6 glial cell line is a classical cell line that was established 
by alternate culture and animal passage after tumor induction 
by iV-nitrosomethylurea. The cell line retained the ability to 
produce the brain-specific protein S-100 [13]. The BNIOIO cell 
line, which derived from an ethylnitrosourea-induced rat CNS 
tumor, was reported to synthesize TRH and to be devoid of 
TRH receptors [12]. Moreover, these cells responded to iso-
proterenol by elevating their intracellular cAMP and exhibit 
sodium flux responses to certain neurotoxin in a manner char-
acteristic of action potential sodium channels. NG108-15 hy-
brids were obtained by fusion of neuroblastoma clone 
N18TG-2 and C6Bu-l a clone of the rat glioma C6 [16]. 
3.2. Kinetic characteristics of f125I-Tyr°JPs4 specific binding to 
C6 rat glioma and BNIOIO cell lines 
The specific [125I-Tyr°]Ps4 binding increased linearly with 
the membrane protein concentration up to 0.3 mg/ml (corre-
lation coefficient = 0.98) (Fig. 1). Higher protein concentra-
tions tended to lower the amount of [125I-Tyr°]Ps4 specifically 
bound because of the increase of proteases concentration and 
viscosity. The time course of [125I-Tyr°]Ps4 specific binding to 
C6 membranes (4°C and 24°C) is shown in Fig. 2A. At 4°C, 
the near maximum specific binding, 5m a x , was reached in 270 
min and the half-time of binding was approximately 40 min. 
Non-specific binding was determined in the presence of 1 uM 
unlabeled [Tyr°]Ps4 and represented 7.5% of the total binding. 
When similar experiments were performed at 24°C, binding 
equilibrium was reached in 150 min and the half-time of bind-
ing was approximately 20 min (Fig. 2A). Addition of 1 (0.M 
unlabeled [Tyr°]Ps4 at equilibrium produced dissociation of 
the bound radioligand, demonstrating the reversibility of 
[125I-Tyr°]Ps4 binding (Fig. 2A, inset). The dissociation kinetic 
obtained at 4°C followed a first-order rate law with a half-
time of dissociation of approximately 38 min. After 180 min, 
almost 70% of the radioiodinated peptide was dissociated. 
However, the dissociation of the receptor-ligand complex 
showed a rather slow decrease at 24°C, with a half-time of 
approximately 138 min (Fig. 2A, inset). After 3 h, only 53% of 
[125I-Tyr°]Ps4 was dissociated. This phenomenon had already 
been observed for Ps4 pituitary binding sites and could be due 
to a conformational change of the receptor after peptide bind-
ing [10]. At 24°C, the rate constants for association (k{) and 
dissociation (k-t) were 4.15 10
7 M"1 min"1 and 7.72 10"3 
min - 1 , respectively. 
The specific binding of [125I-Tyr°]Ps4 to BNIOIO membrane 
homogenates reached equilibrium within the 120 min incuba-
tion at 24°C with a half-time binding value of 11.5 min (Fig. 
2B). Since incomplete dissociation was previously observed 
for pituitary and C6 membranes at room temperature, disso-
ciation experiments were realized on BNIOIO membranes at 
4°C. The results obtained revealed that [125I-Tyr°]Ps4 specific 
binding was reversible (Fig. 2B, inset). The half-time of dis-
sociation was 34.4 min; approximately 77% of the radioiodi-
nated peptide was dissociated after 180 min incubation. Spe-
cific binding was also detected in BNIOIO whole cells at 24°C, 
suggesting a plasma membrane localization for the [125I-
Tyr°]Ps4 binding sites. However, probably due to peptide in-
ternalization or degradation, binding association was very 
slow and 5 m a x was still not reached after 5 h incubation. 
Similar experiments performed on BNIOIO whole cells at 
4°C indicated that 5 m a x is reached after 180 min incubation 
with a half-time of binding of 31.2 min (Fig. 2B). 
3.3. Saturation studies 
Ligand saturation experiments were performed by incubat-
ing C6 membrane preparations with increasing concentrations 
of [125I-Tyr°]Ps4 (16.4 pM to 1.9 nM). Over this concentration 
range, specific binding of [125I-Tyr°]Ps4 was saturable reach-
ing a maximum at approximately 1.9 nM (Fig. 3A, lower 
inset). The non-specific binding, on the contrary, increased 
linearly. At the highest [125I-Tyr°]Ps4 concentration (1.9 nM) 
studied, specific binding represented 61% of the total bound 
ligand while non-specific binding accounted for 38%. Scatch-
ard plot of the binding data gave a straight line (correlation 
coefficient = 0.95) (Fig. 3A), indicating the presence of a single 
class of binding sites for [125I-Tyr°]Ps4 with a K& value of 0.77 
nM and a 5 m a x value of 122 fmol/mg of membrane protein. 
Hill plot (Fig. 3A, upper inset) yielded a nu of 1.07, excluding 
a cooperativity in binding of [125I-Tyr°]Ps4. 
When BNIOIO membranes (final protein concentration — 
3.11 ng/ml) were incubated with increasing concentrations of 
[125I-Tyr°]Ps4 (1.58 pM to 0.75 nM), non-specific binding was 
linear (Fig. 3B, lower inset). In contrast, the specific binding 
of [125I-Tyr°]Ps4 was saturable within the range of concentra-
tions studied. Specific binding accounted for 78% at 0.75 nM 
[125I-Tyr°]Ps4. Scatchard representation of [125I-Tyr°]Ps4 sat-
uration binding isotherm was linear (correlation coeffi-
cient =0.99) (Fig. 3B). These results, together with Hill anal-
ysis (nu = 1.08) (Fig. 3B, upper inset) demonstrated that [125I-
Tyr°]Ps4 bound specifically to a single population of non-
Fig. 3. Saturation binding of [125I-Tyr°]Ps4 to C6 and BNIOIO membranes. A: Scatchard plot of [125I-Tyr°]Ps4 binding to C6 membranes. The 
slope of the line (-ÌIKÌ) was determined by linear regression analysis. Lower inset: Binding of [125I-Tyr°]Ps4 to C6 membrane preparations as 
a function of [125I-Tyr°]Ps4 concentration. Total ( A ) , non-specific (■), and specific (•) binding were estimated as described in Section 2. Values 
are the mean of duplicate incubations. Upper inset: Hill plot of specific binding. The nn determined by linear regression analysis was 1.07. 
B: Scatchard analysis of [125I-Tyr°]Ps4 binding to BNIOIO membranes. Lower inset: Binding of [125I-Tyr°]Ps4 to BNIOIO membrane prepara-
tions as a function of [125I-Tyr°]Ps4 concentration. Total ( A ) , non-specific (■), and specific (•) binding. Upper inset: Hill plot (nn = 1.08). Re-
sults were expressed as described in (A). 
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Fig. 4. Displacement of [125I—Tyr°]Ps4 (0.2 nM) specific binding by Ps4 analogs on C6 membrane homogenates. C6 membranes (90 ug pro-
teins) were incubated for 180 min at 25°C with 0.2 nM [125I—Tyr°]Ps4 and increasing concentrations of the following peptides: ▲ , [Tyr°]Ps4; 
A, [Arg°]Ps4; • . [Arg-1,Arg°]Ps4; □, Ps4. The percentage of specific binding was calculated as 100X(ßs—ßn)/50—Sn) in which BB and Bü are 
the amount bound in the presence and in the absence of competing compound, respectively. Bn is the non-specific binding. The data shown are 
for a single representative experiment. Value for ICgo were determined by regression analysis based upon three independent experiments carried 
out in duplicate. 
interacting high-affinity binding sites. Values of K& and fimax 
were 0.16 nM and 1643 fmol/mg of membrane protein, re-
spectively. 
The Ps4 binding sites are abundantly expressed in BN1010 
cells since more than 105 copies are present per cell. This level 
is comparable to the expression of epidermal growth factor 
receptor [17]. On the other hand, saturation experiments per-
formed on NG108-15 neuroblastoma X glioma hybrid cell 
membranes revealed the presence of a very low amount of 
[125I-Tyr°]Ps4 binding sites (Table 1). In contrast to the parent 
cell C6 which expressed the binding sites at an intermediate 
level (104 copies per cell), less than 103 copies of Ps4 binding 
sites are present in NG108-15. Thus, it seems that the gene(s) 
encoding the TRH-potentiating peptide receptor is partially 
deactivated by hybrid formation. 
3.4. Competition studies 
Competition experiments were carried out by incubating 
membrane preparations with increasing concentrations 
(10~n to 10~4 M) of Ps4 analogues in the presence of 0.2 
nM [125I-Tyr°]Ps4 (Fig. 4). The displacement curves obtained 
gave pseudo-Hill coefficients close to unity and could be best 
Table 1 
Equilibrium binding parameters of [125I-Tyr°]Ps4 binding to different membrane preparations at 24°C 
Cell line Total (cpm) Nonspecific (cpm) KA (nM) 5max (binding sites/cell) 
C6 
BN1010 
NG108-15 
RINm5F 
INS-1 
cxTC 
GH3 
SUG 
SUF 
GC 
2170 
3328 
776 
899 
883 
615 
444 
648 
299 
305 
634 
464 
568 
702 
864 
534 
409 
686 
252 
294 
0.77 
0.16 
0.2 
9700 
130000 
<600 
Values reported are the mean of duplicate determinations of two independent experiments. 
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described by a single-binding site model. The rank order of 
potency of competitors for [125I-Tyr°]Ps4 binding on mem-
branes was [Tyr0]Ps4>[Arg°]Ps4>[Arg"\Arg0]Ps4>Ps4> 
TRH-Ps4. Ki values obtained for [Tyr°]Ps4 (2.5 nM) and 
Ps4 (6.6 uM) were in the same range than those reported 
previously for the pituitary binding sites (4.96 nM and 5.7 
uM, respectively). The two N-terminally extended forms of 
Ps4, prepro-TRH-(159-169) ([Arg°]Ps4) and prepro-TRH-
(158-169) ([Arg— l,ArgO]Ps4), which may be generated by 
an incomplete processing of the pro-TRH, kept the ability 
to inhibit [125I-Tyr°]Ps4 binding. Interestingly [Arg°]Ps4 
(if; = 31.1 nM) was only 12-fold less potent than [Tyr°]Ps4 
(Ki - 2.5 nM). Moreover, the addition of a Arg residue in 
the N-terminal position of [Arg°]Ps4 resulted in a 23-fold 
reduction in receptor binding affinity ([Arg_1,Arg°]Ps4, 
K{ = 712 nM). A more important extension in the N-terminal 
end of Ps4 caused a profound decrease in binding potency, as 
it was demonstrated with prepro-TRH-(154-169) (TRH-Ps4) 
which exhibited a much lower affinity (Ki - 12000.0 nM) than 
Ps4 itself. Of particular interest is the fact that two intermedi-
ate products of TRH-Ps4 to Ps4 conversion exhibit higher 
binding potency than TRH-Ps4 and Ps4 themself. An activa-
tion-deactivation phenomenon of the hormonal message 
could be considered in that case. 
In conclusion, we have identified glial and neural cell line 
that markedly express the high-affinity binding sites for the 
TRH-potentiating peptide. Our data suggest that C6 and 
BN1010 cells represent a Ps4-responsive model for studying 
the mechanism of action of Ps4 at the molecular level. Fur-
thermore, the high number of TRH-potentiating peptide bind-
ing sites in BN1010 cells and the high affinity of the radio-
ligand [125I-Tyr°]Ps4 should enable the molecular 
characterization of the receptor molecule by expression clon-
ing. 
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